RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results
Portfolio Pulse from
RedHill Biopharma is advancing its Crohn's Disease program with a new Phase 2 study for RHB-204, following positive Phase 3 results for RHB-104. The study targets MAP-positive patients and aims for FDA approval by 2025. The Crohn's disease market is expected to grow significantly, offering commercial potential.
March 12, 2025 | 11:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RedHill Biopharma is progressing with its Crohn's Disease program, planning a Phase 2 study for RHB-204 after positive Phase 3 results for RHB-104. The study targets MAP-positive patients and aims for FDA approval by 2025, with significant market growth potential.
The news highlights RedHill Biopharma's progress in its Crohn's Disease program, with a new Phase 2 study for RHB-204 following positive results for RHB-104. The focus on MAP-positive patients and potential FDA approval by 2025, along with expected market growth, suggests a positive impact on RDHL's stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100